In the 57 luminal FMCs, Sox2 was associated with a larger tumor size, more advanced clinical stage, higher histological grades, squamous differentiation, lymphovascular invasion, dermal infiltration, moderate to severe tumor-associated inflammation, higher Ki-67 indexes, and increased numbers of intratumoral Tregs, but lower PR and FOXA1 expression (Supplementary Tables 2, 3). The gene discussed is SOX2; the disease is neoplasm.